Chakravarthi AVPS delivers a notable address on drug safety and leads a pivotal discussion at PHARMAP 2025, playing a crucial role in shaping the future of the pharmaceutical industry.
PHARMAP 2025, a leading pharmaceutical congress in Europe, gathered over 300 top executives from major global pharma firms such as Bayer, Roche, Johnson & Johnson, AstraZeneca, Novartis, Novo Nordisk, Pfizer, Takeda, and others.
The congress highlighted key advancements in the pharmaceutical industry, including the use of digital twin technology in manufacturing and improvements in sustainable packaging. These developments underscored the sector’s move toward interconnected, data-driven, and patient-focused approaches.
Chakravarthi AVPS, a prominent advocate for ethical pharmaceuticals and sustainable packaging, was invited to deliver the Special Address during the opening session. He also led a high-level plenary discussion. His keynote speech, titled “Safe Medicines: A Global Way Forward for Securing Pharmaceutical Integrity and Patient Safety,” emphasized the urgent need to combat the rising threat of counterfeit drugs.
Drawing on historical incidents such as the 1982 Chicago Tylenol case and the complexities of modern global supply chains, Chakravarthi highlighted the importance of traceability, regulatory alignment, and packaging innovation. He stressed that all medicines must be authentic, traceable, and safe, advocating for advanced technologies like RFID, blockchain, and serialization to ensure pharmaceutical integrity.
Chakravarthi identified two critical pathways for ensuring drug safety and integrity:
- Enabling digital traceability in developing nations: This involves the use of scalable technology and public-private partnerships to enhance the traceability of medicines in less developed markets.
- Accelerating global harmonisation: This approach focuses on aligning international standards, such as those from GS1 and ICH, and fostering mutual recognition agreements while respecting national priorities.
Chakravarthi skillfully moderated the session “Navigating Disruption: Innovation in Pharma Supply Chains,” guiding a dynamic conversation on creating resilient and forward-thinking pharmaceutical supply networks. Industry leaders from Takeda, LEO Pharma, NewBridge Pharmaceuticals, and the European Co-Packers Association contributed their expertise, discussing key topics such as AI-driven planning, ethical considerations in automation, and the strategic significance of third-party logistics (3PL) partners.